Long Term Follow-Up Study for rAAV-GAD Treated Subjects

Neurologix, Inc.40 enrolled

Overview

The purpose of this observational study is the long term follow-up of Parkinson's patients who participated in a clinical trial in which they received AAV-GAD gene transfer into the subthalamic nucleus (STN) region of the brain. Patients will be followed once a year for up to five (5) years. The study will monitor and evaluate the long term effects of AAV-GAD and provide long term safety information.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Parkinson's Disease

Interventions

rAAV-GADBIOLOGICAL

Eligibility

Sex: ALLMin age: 30 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participated in a clinical trial where they received AAV-GAD * Able to give informed consent to participate in the study Exclusion Criteria: * Received Deep Brain Stimulation after receiving AAV-GAD * Received any experimental device in the brain after receiving AAV-GAD * Had any type of brain surgery after receiving AAV-GAD * Received any experimental therapy (drug or biologic) for Parkinson's disease or any other indication after receiving AAV-GAD

Locations (6)

Stanford University

Stanford, California, United States

University of Colorado

Aurora, Colorado, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Henry Ford Health Systems

Southfield, Michigan, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.